UCB (OTCMKTS:UCBJF) Sees Large Volume Increase – Still a Buy?

UCB SA (OTCMKTS:UCBJF) shares saw unusually-strong trading volume on Friday . Approximately 4,137 shares traded hands during trading, an increase of 446% from the previous session’s volume of 757 shares.The stock last traded at $285.29 and had previously closed at $281.55.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on UCBJF shares. Wolfe Research started coverage on shares of UCB in a research report on Monday, February 23rd. They set an “outperform” rating for the company. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a research report on Monday, February 16th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The business’s fifty day simple moving average is $295.77 and its two-hundred day simple moving average is $295.36.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.